Fig. 6: The fusion partners of different TKs are largely exclusive.
From: Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers
a Venn diagrams showing the overlap of fusion partners shared between ALK (n = 26 partner genes), RET (n = 9), ROS1 (n = 10), and NTRK1 (n = 6) fusions identified by FACTS. b Comparisons of exon usages of partner genes between different kinase genes. c Quantification of osimertinib-resistant clones in PC-9 cells with fusions induced by between EML4 and different TKs. Data show means of three biological replicates, with error bars representing ±s.e.m; significance was determined by an unpaired, two-tailed Student’s t-test. d Quantification of osimertinib-resistant clones in PC-9 cells with fusions induced by between CD74 and different TKs. Data show means of three biological replicates, with error bars representing ±s.e.m; significance was determined by an unpaired, two-tailed Student’s t-test. e Representative western blot analysis of EML4-ROS1 and CD74-ROS1 fusions after MG-132 treatment. Similar results were observed in n = 2 independent experiments. f Sensitivity to combination of osimertinib plus crizotinib in clones with EML4-ROS1 E6; R34 and CD74-ROS1 C6; R34 fusions. Data show means of three biological replicates, with error bars representing ±s.e.m. Source data are provided as a Source Data file.
